Clinical Trial Update: Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ALXN1840 to standard of care in Wilson disease was terminated, and results were posted on 2023-10-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wilson Disease

Drugs mentioned

• ALXN1840 (ALXN1840)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Wilson Disease | Phase 3 | Status: TERMINATED | Results posted: 2023-10-10